Intelligence · Clinical Development
Pipeline search results
Programs matching “molecular” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 29 pipeline programs matching "molecular" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
2023/3720 UMBRELLA
The George Institute
patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment
1 trial -
4D-150 IVT (3E10 vg/eye)
4D Molecular Therapeutics
Neovascular Age-Related Macular Degeneration (nAMD)
1 trial -
4D-150 IVT (3E10 vg/eye)
4D Molecular Therapeutics
Macular Neovascularization Secondary to Age-Related Macular Degeneration
1 trial -
4D-150-C004
4D Molecular Therapeutics
Macular neovascularization secondary to age-related macular degeneration (nAMD)
1 trial -
4D-125 IVT Injection
4D Molecular Therapeutics
X-Linked Retinitis Pigmentosa
1 trial -
4D-150 IVT
4D Molecular Therapeutics
Diabetic Macular Edema
1 trial -
4D-150 IVT
4D Molecular Therapeutics
Neovascular (Wet) Age-Related Macular Degeneration
1 trial -
4D-310
4D Molecular Therapeutics
Fabry Disease
2 trials -
4D-710
4D Molecular Therapeutics
Cystic Fibrosis Lung
1 trial -
AZD6738, Ceralasertib
AstraZeneca AB
Advanced Cancer Whose Tumours Contain Molecular Alterations
1 trial -
Blautix
4D Molecular Therapeutics
Irritable Bowel Syndrome
1 trial -
CABL001E2201
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response
1 trial -
Low Molecular Weight Heparin (LMWH)
Cardiff Oncology
Cancer
1 trial -
MRx-4DP0004
4D Molecular Therapeutics
COVID-19
1 trial -
MRx0518
4D Molecular Therapeutics
Oncology
1 trial -
MRx0518
4D Molecular Therapeutics
Urothelial Carcinoma
1 trial -
UC-0140/1711_UCBG3
Ningbo Cancer Hospital
Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.
1 trial -
Valemetostat Tosylate, Valemetostat Tosylate
The George Institute
Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.
1 trial -
4D-110
4D Molecular Therapeutics
Choroideremia
1 trial -
CIAG933A12101
Novartis Pharmaceuticals
Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway
1 trial -
MRx-4DP0004
4D Molecular Therapeutics
Asthma
1 trial -
MRx0029
4D Molecular Therapeutics
Idiopathic Parkinson Disease
1 trial -
MRx0518
4D Molecular Therapeutics
Pancreatic Cancer
1 trial -
MRx0518 Capsules
4D Molecular Therapeutics
Melanoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.